Genmab A/S (GMAB) is in Healthcare, Biotechnology, based in Denmark, listed on NasdaqGS. Market cap 22.17B USD. 52-week range 23.62 to 40.17 USD. Trailing P/E 28.4. Data as of 2026-10-09.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for ...